Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) EBITDA Margin: 2009-2024

Historic EBITDA Margin for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to -16.99%.

  • Cumberland Pharmaceuticals' EBITDA Margin fell 505.00% to -23.70% in Q3 2025 from the same period last year, while for Sep 2025 it was -7.90%, marking a year-over-year increase of 2137.00%. This contributed to the annual value of -16.99% for FY2024, which is 717.00% up from last year.
  • According to the latest figures from FY2024, Cumberland Pharmaceuticals' EBITDA Margin is -16.99%, which was up 29.68% from -24.16% recorded in FY2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' EBITDA Margin peaked at -13.58% during FY2022, and registered a low of -24.16% during FY2023.
  • Moreover, its 3-year median value for EBITDA Margin was -16.99% (2024), whereas its average is -18.24%.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' EBITDA Margin spiked by 776bps in 2022, and later crashed by 1,058bps in 2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' EBITDA Margin (Yearly) stood at -17.04% in 2020, then plummeted by 429bps to -21.34% in 2021, then skyrocketed by 776bps to -13.58% in 2022, then tumbled by 1,058bps to -24.16% in 2023, then spiked by 717bps to -16.99% in 2024.